top of page

Biopharma Daily Stock Updates - 01/19/22

$XBI $93.50 | -1.08%


 

Covid Updates

$NVAX -6.2% Australia Therapeutic Goods Administration (TGA) Grants Provisional Registration for Novavax COVID-19 Vaccine source


$SRNE +1.9% Sorrento Announces Completion of Enrollment in US Phase 2 Clinical Trial for COVI-DROPS and Achievement of Interim Analysis Threshold in the UK. source



Pipeline Updates

$MRKR -2.7% MARKER THERAPEUTICS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR ITS MULTI-ANTIGEN TARGETED T CELL THERAPY FOR PANCREATIC CANCER source


$LMNL -1.8% Liminal BioSciences Announces Strategic Priorities For 2022 source


$VYNE -4.2% VYNE Therapeutics Announces Phase 1b Data for FMX114 from Phase 1b/2a Trial for the Treatment of Mild-to-Moderate Atopic Dermatitis. source


$CCXI -3.9% ChemoCentryx Announces EU Approval of TAVNEOS® (avacopan) for the Treatment of ANCA-Associated Vasculitis. source


$AKTX +4.2% FDA Agrees to Use of New Higher-Yielding Manufacturing Process for Nomacopan in Pivotal Clinical Studies. source


$SPRO -1.9% Spero Therapeutics Awarded up to an Additional $12.9 Million by BARDA to Support the Development of Orally Administered Tebipenem Pivoxil in Pediatric Patients. source


$CTMX +6.5% CytomX Therapeutics Announces FDA Clearance of Investigational New Drug Application for CX-904 for the Treatment of Advanced Solid Tumors. source


$GMDA +22.5% Gamida Cell Provides Update on Omidubicel BLA Submission. source


$HCM -2.7% HUTCHMED Highlights Fruquintinib Clinical Data to be Presented at the 2022 ASCO Gastrointestinal Cancers Symposium. source



Business Updates

$EVFM +22.9% Evofem Biosciences Announces Record Net Sales and Phexxi Prescriptions in Q4 2021. source


$ADMA +3.7%ADMA Biologics Announces Record Preliminary Fourth Quarter and Full Year 2021 Revenues and Provides 2022 Business Update. source


$OSMT -0.9% Osmotica Pharmaceuticals plc Announces Corporate Name Change to RVL Pharmaceuticals plc, New Ticker Symbol “RVLP,” Plans to Launch UPNEEQ® into the Medical Aesthetics Market, and Provides Fourth Quarter 2022 Net Sales Guidance. source


 

Posted by FS/JM

0 comments

Comentários


bottom of page